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Abstract
Background: Adjusting medication for uncontrolled asthma involves selecting one of several options from the
same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing
budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART
® Turbuhaler
®) in patients
previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4.
Methods: This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/
FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both
current clinical asthma control during the last week of treatment and exacerbations during the study were
examined.
Results: At each GINA treatment step, the proportion of patients achieving target levels of current clinical control
were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher
fixed maintenance dose of inhaled corticosteroid/long-acting b2-agonist (ICS/LABA) (plus short-acting b2-agonist
[SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and
reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher
maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly
higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared
with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all
treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps.
Conclusions: BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to
4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is
most effective in the higher treatment steps.
Background
A major objective of the 2006 revision of the Global
Initiative for Asthma (GINA) guidelines [1] was to sim-
plify the process of assessing patients’ treatment needs
at both initial and follow-up visits. Instead of assessing
“asthma severity” using severity classification tables, a
simplified assessment of current asthma control is
recommended and treatment is either initiated or
altered according to the assessed control status. This
approach has, with some modification, been adopted in
most international and recent versions of national treat-
ment guidelines and has been well received by practis-
ing clinicians [2]. Central to this approach are the
treatment steps defining initial maintenance treatment
and recommendations for stepping up or stepping down
treatment. These are based on treatment response -
whether or not current clinical control is achieved and
maintained. Thus, patients failing Step 2 treatment, on
a low dose of inhaled corticosteroid (ICS), might be
m o v e du pt oS t e p3w h e r et h ep r e f e r r e do p t i o nf o r
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b2-agonist (LABA). At Step 4, an increase in ICS dose
or the addition of another controller medication (e.g. a
leukotriene modifier or sustained-release theophylline)
is recommended in order to achieve control. However,
in the significant proportion of patients in which con-
trol is not achieved, Step 5 management may be consid-
ered, recognising that lack of control is associated with
a higher risk of exacerbations, poor quality of life and
other adverse outcomes [2].
For patients whose asthma is uncontrolled on Step 2
or higher treatment, a recent strategy included in GINA
guidelines is the use of a combination inhaler containing
budesonide and formoterol for both maintenance ther-
apy and relief of symptoms (option for Steps 3-5). This
approach has been shown in several large-scale rando-
mised controlled trials to achieve similar current clinical
control of asthma and to be superior to comparators in
reducing asthma exacerbations [3-7]. These results have
been achieved with the use of significantly lower doses
of inhaled and systemic corticosteroids [3-6]. The com-
parators in these studies have been either a two- to
four-fold higher dose of budesonide (a Step 2-3 option)
[ 3 , 4 ] ,t h es a m ed o s eo fI C Sp l u saL A B A( aS t e p3
o p t i o n )o rah i g h e r - d o s eI C Sp l u saL A B A( aS t e p4
treatment), together with a short-acting b2-agonist
(SABA) for as-needed relief of symptoms [3,5-7]. Recent
post hoc analyses of the results of these studies have
provided further insights into the relationship between
levels of current asthma control achieved and “future
risk” [8-10]. From the clinician’s perspective, the deci-
sion to consider a change in medication will usually be
prompted by a patient’s failure to achieve control on
current treatment (Steps 2-4). It is therefore appropriate
to examine the relative benefit of introducing budeso-
nide/formoterol (BUD/FORM) maintenance and reliever
therapy in patients previously prescribed different GINA
steps of treatment. We report here a post hoc analysis of
the results of five clinical trials comparing BUD/FORM
maintenance and reliever therapy with comparator treat-
ments when introduced in patients on different treat-
ment steps (Steps 2-4) according to GINA guidelines at
study entry.
Methods
Objectives
This pooled analysis describes the relative effect of
BUD/FORM maintenance and reliever therapy on cur-
rent asthma control and on exacerbation risk, compared
with fixed-dose maintenance regimens of ICS or combi-
nation ICS/LABA, plus SABA as reliever, in patients
with asthma stratified by GINA treatment step at study
entry.
Studies and population
The clinical studies included in this retrospective analy-
sis involved >12000 patients from five double-blind, ran-
domised, parallel-group trials (6-12 months’ duration)
with exacerbation as a primary variable. The trials inves-
tigated the efficacy of BUD/FORM maintenance and
reliever therapy (Symbicort SMART
® Turbuhaler
®,
AstraZeneca AB, Lund, Sweden) versus comparator
therapies which included: higher maintenance dose ICS
(budesonide) plus SABA as needed [3,4]; same mainte-
nance dose ICS/LABA (BUD/FORM, Symbicort
®, Astra-
Zeneca, Lund, Sweden) plus SABA as needed [3,7]; and
higher maintenance dose ICS/LABA (BUD/FORM [5] or
salmeterol/fluticasone [Seretide™,G l a x o S m i t h K l i n e ,
Uxbridge, UK]) plus SABA as needed [5,6]. In all studies
the SABA used was terbutaline (Bricanyl
®, AstraZeneca,
Sweden; 0.4 mg/inhalation) and all aforementioned
drugs were administered via Turbuhaler
® (AstraZeneca,
Lund, Sweden) except for salmeterol/fluticasone which
was delivered via either Diskus™ or Evohaler™ (Glax-
oSmithKline, Uxbridge, UK).
The methodologies of the five studies have been pub-
lished in detail previously [3-7]. Further details of each
of these studies are provided in the additional files (see
Additional file 1, Table S1 of the additional files). All
five studies were performed in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines and were approved by independent ethics
committees. Written informed consent was obtained
from each adult patient; for patients under 18 years of
age, informed consent was obtained from both the
patient and his/her legal guardian. As this retrospective
analysis is based on these five studies no additional
approvals were applied for.
Stratification by GINA treatment step at entry
Patients with asthma at least 12 years of age who were
symptomatic during run-in were randomised. Data col-
lected at study entry were used to classify each
patient’s pre-study asthma medication as Step 2, 3 or 4
according to GINA classification based on ICS dose
and use of other controller medication. In all studies
the regular use of ICS was an inclusion criterion but
use of systemic steroids within 30 days of study entry
was an exclusion criterion - thus patients on either
Step 1 or Step 5 were excluded[3-7]. The GINA treat-
ment steps were defined as:
￿ Step 2 - low-dose ICS
￿ Step 3 - low-dose ICS plus at least one of a LABA,
a leukotriene receptor antagonist (LTRA) or
xanthine, or medium- to high-dose ICS alone
￿ Step 4 - medium- to high-dose ICS plus at least
one of a LABA (including high-dose ICS/LABA
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1, Tables S2 and S3).
Assessments
Asthma control as defined by GINA criteria
Each patient’s asthma control, defined by GINA guide-
line-derived criteria (Controlled, Partly Controlled or
Uncontrolled asthma) [2], was determined retrospec-
tively each week from diary data in the studies. In this
report, we have considered only the results from the last
week of the run-in period and the last week of the study
[9]. Where there was insufficient diary data to perform
an assessment of control, the week was considered
Uncontrolled.
FEV1
Forced expiratory volume in 1 second (FEV1)w a s
recorded at clinic visits and the percentage of predicted
normal was calculated. At the study entry visit pre- and
post-bronchodilator FEV1 was recorded and for all sub-
sequent visits patients were requested to take their
morning study medication as usual.
Reliever use
Reliever use per patient per 24 hours was derived from
diary cards and summarised as mean over the last 10
days of run-in and over the study period.
Exacerbations
Due to minor differences in the definition of exacerba-
tions across the original studies, the definition of exacer-
bations in this pooled analysis was standardised to a
worsening of asthma symptoms requiring an oral steroid
course of at least 3 days’ duration, an emergency room
(ER) visit or a hospitalisation for treatment of asthma.
For more details of the definitions of control and
exacerbations please refer to the additional files.
Statistical methods
The main purpose of the analysis was to estimate the
effect of BUD/FORM maintenance and reliever therapy
versus a comparator for each individual GINA treatment
step at entry. P-values below 5% were regarded as indi-
cating statistical significance.
The percentage of patients in each control state dur-
ing the last study week was presented by treatment and
GINA treatment step and analysed in two separate
logistic regression models - one for the odds of being
Controlled and one for the odds of being at least Partly
Controlled - both with factors including treatment,
GINA treatment step, treatment-GINA treatment step
interaction and study. The number of exacerbations was
presented as yearly exacerbation rates by GINA treat-
ment step and treatment and analysed using a Poisson
model with factors including treatment, GINA treat-
ment step, treatment-GINA treatment step interaction
and study, and observation time as an offset, with
adjustments performed for overdispersion if present.
Time to first exacerbation was described by Kaplan-
Meier plots stratified by treatment and GINA treatment
step and analysed in a Cox proportional hazard model
with factors including treatment, GINA treatment step
and treatment-GINA treatment step at entry interac-
tion, stratified by study. The same models were applied
to hospitalisations and ER treatments.
T h ec h a n g ei nF E V 1 as percentage of predicted nor-
mal, from randomisation to last visit on treatment, was
analysed using analysis of variance (ANOVA) with the
same factors as above and with the value at randomisa-
tion as a covariate. In calculating mean FEV1 over time
by GINA treatment step and treatment group the last
observation carried forward principle was used to cor-
rect for missing values. In the plot of this data, as visits
occurred at different intervals in the studies, values were
positioned with the month nearest to the study visit.
Thus the 1- and 3-month-visit data from the Bousquet
et al. study were plotted with the 2- and 4-month-visit
data from the Kuna et al. study, and the 4- and 8-
month-visit data from the Rabe et al. study were plotted
with the 3- and 9-month data from the O’Byrne et al.
and the Scicchitano et al. study, respectively [3-7]. In
addition, a 6-month value was imputed for patients in
the Rabe et al. study as the mean of the 4- and 8-
month-visit values [7].
Patient means of daily reliever use during the treat-
ment period were analysed using ANOVA analysis of
variance with the same factors as above and with mean
reliever use during run-in as a covariate.
Results
GINA treatment steps at entry and demographics
A total of 12512 subjects were included in the analysis
described; only one patient included in the original trials
lacked data on pre-entry medication and was excluded
from the analysis. The numbers of patients defined as
being at GINA treatment Steps 2, 3 or 4 at entry were
1037, 6352 and 5123 respectively. All patients used ICS,
45% used LABA, 5% used theophylline, 3% used LTRAs
and ≤ 2% used anticholinergics, cromones or oral b2-
agonists (see Additional file 1, Table S3 in additional
files).
Baseline characteristics were similar between compara-
tor treatment groups in this pooled analysis (Table 1).
By categorising patients by their GINA treatment step at
entry, some differences were evident between the steps
for patient age and FEV1 but mean total symptom
scores were similar.
Asthma control defined by GINA criteria
In the final week of treatment, the proportion of
patients with GINA-defined Controlled asthma and
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Page 3 of 11Table 1 Baseline characteristics of study subjects
Budesonide/formoterol maintenance and reliever therapy vs. higher maintenance dose ICS + SABA
Step 2 Step 3 Step 4
Higher
maintenance ICS
+ SABA
(N = 262)
BUD/FORM
maintenance and
reliever therapy
(N = 231)
Higher
maintenance ICS
+ SABA
(N = 1013)
BUD/FORM
maintenance and
reliever therapy
(N = 1051)
Higher
maintenance ICS
+ SABA
(N = 769)
BUD/FORM
maintenance and
reliever therapy
(N = 747)
Male, n (%) 123 (47) 104 (45) 399 (39) 433 (41) 318 (41) 315 (42)
Age, mean 30.6 32.2 39.5 37.5 42.6 42.0
ICS, n (%) Low 262 (100) 231 (100) 242 (24) 226 (22) 0 0
Medium 0 0 664 (66) 711 (68) 643 (84) 591 (79)
High 0 0 107 (11) 114 (11) 126 (16) 156 (21)
LABA use,
n (%)
0 0 221 (22) 214 (20) 706 (92) 689 (92)
Asthma
diagnosis,
median years
6.5 9 10 9 10 9
FEV1, % PN 74.3 74.5 72.5 72.8 71.2 72.3
As-needed use,
mean daily
2.16 2.24 2.03 2.08 2.26 2.12
Symptom
score, mean
total
1.36 1.37 1.57 1.63 1.74 1.65
Budesonide/formoterol maintenance and reliever therapy vs. same maintenance dose ICS/LABA + SABA
Step 2 Step 3 Step 4
Same
maintenance ICS/
LABA + SABA
(N = 375)
BUD/FORM
maintenance and
reliever therapy
(N = 389)
Same
maintenance ICS/
LABA + SABA
(N = 896)
BUD/FORM
maintenance and
reliever therapy
(N = 883)
Same
maintenance ICS/
LABA + SABA
(N = 596)
BUD/FORM
maintenance and
reliever therapy
(N = 597)
Male, n (%) 157 (42) 170 (44) 389 (43) 391 (44) 274 (46) 250 (42)
Age, mean 35.3 34.7 39.4 37.7 42.6 43.4
ICS, n (%) Low 375 (100) 389 (100) 130 (15) 136 (15) 0 0
Medium 0 0 671 (75) 644 (73) 415 (70) 411 (69)
High 0 0 95 (11) 103 (12) 181 (30) 186 (31)
LABA use,
n (%)
0 0 107 (12) 118 (13) 548 (92) 548 (92)
Asthma
diagnosis,
median years
8 9 11 10 12 13
FEV1, % PN 72.5 73.7 71.9 72.1 70.8 70.3
As-needed use,
mean daily
2.01 1.98 2.17 2.18 2.34 2.23
Symptom
score, mean
total
1.62 1.56 1.68 1.65 1.78 1.76
Budesonide/formoterol maintenance and reliever therapy vs. higher maintenance dose ICS/LABA + SABA
Step 3* Step 4
Higher
maintenance ICS/
LABA + SABA
(N = 1786)
BUD/FORM
maintenance and
reliever therapy
(N = 1203)
Higher
maintenance ICS/
LABA + SABA
(N = 1585)
BUD/FORM
maintenance and
reliever therapy
(N = 1051)
Male, n (%) 716 (40) 498 (41) 654 (41) 420 (40)
Age, mean 36.2 36.3 40.9 41.7
ICS, n (%) Low 124 (7) 139 (12) 0 0
Medium 1424 (80) 918 (76) 1283 (81) 876 (83)
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increasing GINA treatment step, irrespective of study
treatment (Figures 1A and 1B). The proportion of
patients with Controlled asthma was higher for all
GINA treatment steps when BUD/FORM maintenance
and reliever therapy was compared with higher mainte-
nance dose ICS + SABA (13-23% vs. 9-16%, respectively)
and was statistically significant for GINA treatment
Steps 2 (P = 0.03) and 3 (P < 0.01). The proportion of
patients with Controlled asthma was similar for all
GINA treatment steps when BUD/FORM maintenance
and reliever therapy was compared with same mainte-
nance dose ICS/LABA + SABA (16-22% vs. 14-21%) and
h i g h e rm a i n t e n a n c ed o s eI C S / L A B A+S A B A( 1 6 - 2 0 %
vs. 16-21%) (Figure 1A).
The proportion of patients with Controlled or Partly
Controlled asthma was significantly higher for all GINA
treatment steps when BUD/FORM maintenance and
reliever therapy was compared with higher maintenance
dose ICS + SABA (49-61% vs. 37-53% of patients; P <
0.05). The proportion of patients with Controlled or
Partly Controlled asthma was at least similar for all
treatment steps when BUD/FORM maintenance and
reliever therapy was compared with same maintenance
dose ICS/LABA + SABA (52-61% vs. 45-63%) and was
significantly higher for GINA treatment Step 4 patients
(P = 0.011). When compared with higher maintenance
dose ICS/LABA + SABA the proportion of patients with
Controlled or Partly Controlled asthma was similar for
BUD/FORM maintenance and reliever therapy for both
GINA treatment steps assessed (50-59% vs. 51-58%)
(Figure 1B).
FEV1
On average, higher GINA treatment steps at entry were
associated with a lower FEV1 both before and during
study treatment. Following randomisation, mean FEV1
increased during treatment, with a tendency to reach a
plateau earlier in higher GINA treatment steps. BUD/
FORM maintenance and reliever therapy gave a signifi-
cantly larger increase in FEV1 for all GINA treatment
steps compared with higher maintenance dose ICS +
SABA (mean FEV1 80.0-88.5 vs. 76.8-86.4) and for Steps
3a n d4w h e nc o m p a r e dw i t ht h es a m em a i n t e n a n c e
ICS/LABA + SABA group (mean FEV1 85.1-88.4 vs.
82.9-85.9). Mean FEV1 was similar in the BUD/FORM
maintenance and reliever therapy group and the higher
maintenance dose ICS/LABA + SABA group at the end
of the study (84.8-89.1 vs. 84.7-89.1) (Figure 2).
Reliever use
Patients in the higher GINA treatment steps at entry
used more reliever medication (SABA or ICS/LABA as
reliever) on average during the study than those in
lower GINA treatment steps. Mean reliever use was sig-
nificantly lower in patients receiving BUD/FORM main-
tenance and reliever therapy compared with higher
maintenance dose ICS + SABA (0.737-1.165 vs. 1.100-
1.734; P < 0.001) and same maintenance dose ICS/
LABA + SABA (0.924-1.195 vs. 1.119-1.502; P < 0.001)
at all GINA treatment steps apart from the Step 2 sub-
group comparison with same maintenance dose ICS/
LABA + SABA (0.834 vs. 0.928). When BUD/FORM
maintenance and reliever therapy was compared with
higher maintenance dose ICS/LABA + SABA there were
no differences between study treatments in reliever use
in either of the GINA treatment steps (0.874-1.105 vs.
0.889-1.143) (Additional file 1, Figure S1).
Exacerbations
The rate of exacerbations during study treatment gener-
ally increased with increasing GINA treatment step at
entry (Figure 3). BUD/FORM maintenance and reliever
therapy significantly reduced the rate of exacerbations in
Table 1 Baseline characteristics of study subjects (Continued)
High 238 (13) 146 (12) 302 (19) 175 (17)
LABA use, n
(%)
119 (7) 138 (11) 1527 (96) 1004 (96)
Asthma
diagnosis,
median years
11 11 10 12
FEV1, % PN 72.7 71.9 71.4 70.4
As-needed use,
mean daily
2.28 2.26 2.34 2.27
Symptom
score, mean
total
1.95 1.91 1.88 1.88
BUD/FORM = budesonide/formoterol; FEV1 = forced expiratory volume in 1 second; ICS = inhaled corticosteroid; LABA = long-acting b2-agonist; PN = predicted
normal; SABA = short-acting b2-agonist.
*Seven Step 2 classified patients were pooled with Step 3.
GINA steps were assigned according to treatment at study entry.
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pared with higher maintenance dose ICS + SABA (0.177
and 0.303 vs. 0.411 and 0.486) in all GINA treatment
steps compared with same maintenance dose ICS/LABA
+ SABA (0.141-0.276 vs. 0.254-0.532) and in GINA
treatment Step 4 patients compared with higher mainte-
nance dose ICS/LABA + SABA (0.313 vs. 0.470) (Figure
3). In the remaining two groups, although exacerbations
were numerically lower with BUD/FORM maintenance
and reliever therapy the differences did not reach
statistical significance (GINA treatment Step 2 patients
vs. higher maintenance dose ICS + SABA [0.144 vs.
0.174], and GINA treatment Step 3 patients vs. higher
maintenance dose ICS/LABA + SABA [0.198 vs. 0.250])
(Figure 3).
In all three comparisons, fewer patients receiving
BUD/FORM maintenance and reliever therapy experi-
enced a severe exacerbation compared with the fixed-
dose controller regimens plus SABA: BUD/FORM main-
tenance and reliever therapy vs. higher maintenance
Figure 1 Proportion of Controlled or Partly Controlled asthma patients in final week of treatment by study treatment and GINA
treatment step at entry. BUD/FORM = budesonide/formoterol; ICS = inhaled corticosteroid; LABA = long-acting b2-agonist; OR = odds ratio;
SABA = short-acting b2-agonist.
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(20.9%), respectively [3,4]; BUD/FORM maintenance
and reliever therapy vs. same maintenance dose ICS/
LABA + SABA, 247 patients (12.2%) vs. 437 patients
(21.4%), respectively [3,7]; and BUD/FORM maintenance
and reliever therapy vs. higher maintenance dose ICS/
LABA + SABA, 202 patients (9.0%) vs. 394 patients
(11.7%), respectively [5,6].
In general, higher GINA treatment steps were asso-
ciated with a shorter time to first event for all treatment
groups (Figure 4). Within each GINA treatment step,
the BUD/FORM maintenance and reliever therapy
Figure 2 Mean FEV1 by visit and GINA step at study entry. BUD/FORM maintenance and reliever therapy vs. higher maintenance dose ICS +
SABA, difference at last visit as percentage predicted normal, adjusted for FEV1 at randomisation visit (95% confidence interval): Step 2, 2.18 (0.22,
4.14); Step 3, 3.58 (2.29, 4.87); Step 4, 3.83 (2.25, 5.40). BUD/FORM maintenance and reliever therapy vs. same maintenance dose ICS/LABA +
SABA, difference at last visit as percentage predicted normal, adjusted for FEV1 at randomisation visit (95% confidence interval): Step 2, 1.29
(-1.29, 3.88); Step 3, 2.50 (1.25, 3.76); Step 4, 2.70 (1.24, 4.17). BUD/FORM maintenance and reliever therapy vs. higher maintenance dose ICS/LABA
+ SABA, difference at last visit as percentage predicted normal, adjusted for FEV1 at randomisation visit (95% confidence interval): Step 3, 0.22
(-0.82, 1.26); Step 4, 0.53 (-0.57, 1.64).
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event compared with all three comparator fixed-dose
maintenance regimens + SABA.
Relatively few events (<5% of patients) required hospi-
tal treatment or an ER visit during the study period in
all groups, except among patients classified as GINA
treatment Step 4 receiving same or higher maintenance
dose ICS/LABA + SABA, for which 7.8% and 6.0% of
patients required hospitalisation or an ER visit, respec-
tively. However, most comparisons (rate and time to
first exacerbation) favoured the BUD/FORM mainte-
nance and reliever therapy group (Additional file 1,
Table S4).
Discussion
For ease of use, pharmacotherapy in asthma guidelines
is arranged in treatment steps. Increasing treatment in
patients who require additional treatment medication
involves selecting an option from among the treatments
on the same or a higher step. Treatments are stratified
on the basis of randomised trials comparing their effi-
cacy in patients qualifying for that treatment step with
due regard to their therapeutic index, that is, weighing
up benefit and safety. The results of this post hoc analy-
sis of five large clinical studies provides clinically useful
information on the relative efficacy and benefits of
BUD/FORM maintenance and reliever therapy com-
pared with high-dose ICS or fixed-dose ICS/LABA
combinations plus SABA when introduced in patients
previously prescribed treatments at Steps 2, 3 or 4 in
the GINA report.
Satisfactory control, defined as Controlled or Partly
Controlled asthma in the GINA report, was achieved in
at least as many, or, for some comparisons and treat-
ment steps, in a higher proportion of patients treated
with BUD/FORM maintenance and reliever therapy
compared with other fixed-dose maintenance regimens
+ SABA. For most comparisons, this was achieved with
a lower mean dose of ICS and was associated with a
lower risk of exacerbations (future risk). From the pri-
mary analyses of each of these trials, it is clear that
lower exacerbation rates also resulted in significantly
lower requirements for short courses of oral corticoster-
oids [3-7].
The superiority of BUD/FORM maintenance and relie-
ver therapy over higher maintenance dose ICS alone
with SABA as reliever in achieving satisfactory control
(defined as Controlled or Partly Controlled by GINA)
for patients previously prescribed Step 2 treatment is an
important observation. This analysis suggests that using
BUD/FORM both as maintenance and reliever for
patients not controlled at this treatment step offers sig-
nificant benefit. Secondly, BUD/FORM maintenance and
reliever therapy at Steps 3 and 4 is also superior to
fixed-dose ICS/LABA given at the same maintenance
dose of ICS in achieving reductions in exacerbations,
although it is only in patients at Step 4 that a statisti-
cally significant advantage is seen in current clinical
control. Finally, BUD/FORM maintenance and reliever
therapy achieves only similar levels of current clinical
control to a higher maintenance dose of ICS/LABA but
retains its advantage in reducing exacerbations (only sta-
tistically significant in patients on Step 4), making it an
attractive option in patients on this step for reducing
exposures to inhaled and systemic corticosteroids.
These results are supported by the changes in FEV1
and as-needed use of reliever medication. Improvements
in FEV1 were significantly greater with BUD/FORM
maintenance and reliever therapy for all comparisons
other than at Step 2 when compared with same mainte-
nance dose ICS/LABA + SABA and with a higher main-
tenance dose of ICS/LABA + SABA. The reduction in
reliever use was significant in the comparison with a
higher maintenance dose ICS + SABA in Steps 2-4 and
Steps 3 and 4 when compared with same maintenance
dose ICS/LABA + SABA.
A further finding of the analysis is the relationship
between treatment step and other indicators of asthma
severity. A recent American Thoracic Society/European
Respiratory Society Task Force Report on asthma sever-
ity and control states that the level of treatment
required to achieve and/or maintain control is the most
Figure 3 Exacerbation rate by study treatment and GINA
treatment step at study entry. BUD/FORM = budesonide/
formoterol; ICS = inhaled corticosteroid; LABA = long-acting b2-
agonist; SABA = short-acting b2-agonist BUD/FORM maintenance
and reliever therapy vs. higher maintenance dose ICS + SABA,
exacerbation rate ratio (95% confidence interval): Step 2, 0.829
(0.570, 1.207); Step 3, 0.431 (0.353, 0.526); Step 4, 0.624 (0.512, 0.761).
BUD/FORM maintenance and reliever therapy vs. same maintenance
dose ICS/LABA + SABA, exacerbation rate ratio (95% confidence
interval): Step 2, 0.583 (0.389, 0.874); Step 3, 0.455 (0.371, 0.558); Step
4, 0.519 (0.434, 0.620). BUD/FORM maintenance and reliever therapy
vs. higher maintenance dose ICS/LABA + SABA, exacerbation rate
ratio (95% confidence interval): Step 3, 0.795 (0.631, 1.002); Step 4,
0.665 (0.549, 0.807).
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Page 8 of 11Figure 4 Time to first severe exacerbation by GINA treatment step at study entry. BUD/FORM = budesonide/formoterol; ICS = inhaled
corticosteroid; LABA = long-acting b2-agonist; SABA = short-acting b2-agonist P-values refer to Cox model. BUD/FORM maintenance and
reliever therapy vs. higher maintenance dose ICS + SABA, hazard ratio (95% confidence interval): Step 2, 0.545 (0.341, 0.870); Step 3, 0.507 (0.401,
0.642); Step 4, 0.701 (0.546, 0.900). BUD/FORM maintenance and reliever therapy vs. same maintenance dose ICS/LABA + SABA, hazard ratio (95%
confidence interval): Step 2, 0.467 (0.268, 0.814); Step 3, 0.516 (0.406, 0.656); Step 4, 0.561 (0.449, 0.700). BUD/FORM maintenance and reliever
therapy vs. higher maintenance dose ICS/LABA + SABA, hazard ratio (95% confidence interval): Step 3, 0.726 (0.554, 0.950); Step 4, 0.773 (0.620,
0.965).
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Page 9 of 11consistent indicator of severity [11]. In our analysis,
patients on higher treatment steps at entry were older
(less than 10 years’ mean difference between Steps 2
and 4), possibly indicating increasing treatment require-
ments associated with lifelong asthma, and there was a
trend towards lower FEV1 and higher symptom scores
during run-in. Consistent with this, the proportion of
patients with GINA-defined Controlled asthma and
Controlled or Partly Controlled asthma at study end
decreased with increasing GINA treatment step at entry,
irrespective of study treatment. These results are also
consistent with those of the Gaining Optimal Asthma
Control (GOAL) study in which the proportion of
patients achieving target levels of control decreased with
increasing severity of asthma categorised according to
prior treatment. This was in spite of escalation of ICS
or fixed-dose ICS/LABA to maximum recommended
levels for a prolonged period [12].
The limitations of this study include that it is a post hoc
analysis; patients were not randomised according to
GINA treatment step in each study. The assessment of
GINA-defined asthma control was also post hoc and
based upon data derived from patient diary cards; how-
ever, the method that was employed and its usefulness
have been discussed in a previous report [9]. A further
limitation is that, although in all the studies asthma
symptoms and reliever use during run-in confirmed that
patients were uncontrolled at entry, in three of the five
studies some medications had been withdrawn during
this phase, resulting in worse control than at recruitment.
While this will have served to emphasise the benefits of
subsequent treatments, it would not have favoured any of
the treatments. In only one study was the control state
known prior to run-in, and in this study the five-item
Asthma Control Questionnaire score was higher than
2.1, confirming that the majority of those recruited were
uncontrolled [7]. Furthermore, the numbers of patients
on Step 2 treatment and the relatively low exacerbation
rates in this subgroup weakens the confidence of the esti-
mate. Finally, because of the relatively short duration of
the studies (6-12 months), we have not attempted to
study other aspects of future risk such as lung function
decline or the adverse effects of treatment. However, a
recent combined analysis of these five and one additional
study comparing BUD/FORM maintenance and reliever
therapy with fixed-dose alternatives confirmed that the
former was associated with fewer asthma-related serious
adverse events and discontinuations during the studies
and with no increased risk of deaths or cardiac-related
serious adverse events [13].
Conclusions
In summary, this analysis confirms that the BUD/FORM
maintenance and reliever therapy approach is a highly
effective option for patients requiring treatment adjust-
ments across Steps 2 to 4 in the GINA treatment guide-
lines. The as-needed use of BUD/FORM for relief is
obviously of greatest benefit to patients in each treatment
step whose asthma control is not optimal, either because
they are undertreated or because their asthma is more
refractory (severe). The reduction in such patients’ rates of
asthma exacerbations, with attendant reduction in need
for systemic corticosteroids, is a useful advantage and,
although not examined in this analysis, might be asso-
ciated with reductions in risk of adverse effects of treat-
ment, particularly in the long term.
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